Cagrilintide: difference between revisions
Diff·revision 21 → 22·04:31, 1 Sep 2025
Difference between revision 21 and revision 22 of Cagrilintide. 2 lines changed; the page grew by 204 bytes.
| Revision 21 — 22:34, 4 Aug 2025 DrTitration (talk) clarify that the peptide backbone is acylated rather than PEGylated 4,052 bytes ±0 | Revision 22 — 04:31, 1 Sep 2025 SecondarySrc_Seb (talk) rm duplicated pharmacokinetics — the same figures appear in the infobox 4,256 bytes +204 | ||
|---|---|---|---|
| 34 | Analytically it presents the difficulty common to amylin analogues: residual aggregation propensity means that size-based methods carry weight a [[Reverse-phase HPLC|reverse-phase]] purity determination cannot supply, since aggregates dissociate under reverse-phase conditions. See [[Peptide aggregation]].{{r|usp1503}} | 34 | Analytically it presents the difficulty common to amylin analogues: residual aggregation propensity means that size-based methods carry weight a [[Reverse-phase HPLC|reverse-phase]] purity determination cannot supply, since aggregates dissociate under reverse-phase conditions. See [[Peptide aggregation]].{{r|usp1503}} |
| 35 | 35 | ||
| + | 36 | As with [[Retatrutide|retatrutide]], no marketed product means no generally available [[Reference standard|reference standard]], so identity rests on mass agreement with a calculated value.{{r|usp1503}} | |
| + | 37 | ||
| 36 | == References == | 38 | == References == |
| 37 | {{reflist}} | 39 | {{reflist}} |